{"nctId":"NCT00773968","briefTitle":"A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia","startDateStruct":{"date":"2008-09"},"conditions":["Anemia"],"count":140,"armGroups":[{"label":"Methoxy Polyethylene Glycol-Epoetin Beta","type":"EXPERIMENTAL","interventionNames":["Drug: Methoxy Polyethylene Glycol-Epoetin Beta"]}],"interventions":[{"name":"Methoxy Polyethylene Glycol-Epoetin Beta","otherNames":["CERA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic renal anemia;\n* Continuous subcutaneous maintenance darbopoetin alfa treatment during previous month;\n* Hb concentration between 10 and 12 g/dL;\n* Adequate iron status.\n\nExclusion Criteria:\n\n* Transfusion of red blood cells during previous 2 months;\n* Significant acute or chronic bleeding, such as overt gastrointestinal bleeding;\n* Poorly controlled hypertension requiring hospitalization or interruption of darbopoetin alfa treatment in the previous 6 months;\n* Active malignant disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Maintaining Their Mean Hb Concentration Within Plus/Minus (±) 1 Grams Per Deciliter (g/dL) of the Reference Range and Between 10.0 and 12.0 g/dL During Efficacy Evaluation Period (EEP)","description":"The reference Hb was defined as the average Hb concentration calculated on the basis of all Hb assessments taken at Weeks -4, -2, and 0 (before the first dose administration).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hb Concentrations Between EEP and Stability Verification Period (SVP)","description":"Hb concentrations during SVP were the reference Hb concentrations. For each assessment period (SVP and EEP) the average Hb concentration was calculated on the basis of all Hb assessments taken during the assessment period. Change in average Hb concentration from reference range (SVP) was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Maintaining Hb Concentrations Within the Range of 10.0 to 12.0 g/dL Throughout EEP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time Spent in the Hb Range of 10.0 to 12.0 g/dL During the EEP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Any Dose Adjustment During Dose Titration Period (DTP) and EEP","description":"The methoxy polyethylene glycol-epoetin beta dose adjustment (dose increase or decrease) was required: if a single Hb concentration was either greater than or equal to (≥) 13 g/dL or less than or equal to (≤) 9 g/dL; if the difference of 2 consecutive Hb concentrations was ≥2 g/dL; when the values of scheduled Hb assessments on the days of drug administration and on the previous study visit were both out of range of 10.5 to 11.5 g/dL and the difference between the reference value (average Hb concentration calculated on the basis of all Hb assessments taken at Weeks -4, -2, and 0) and the most recent value was \\>1 g/dL; and when the values of scheduled Hb assessments on the days of drug administration and on the previous study visit were both out of range of 10 to 12 g/dL. Dose adjustment could be made at any time at the discretion of the clinician if clinically warranted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Required Red Blood Cell Transfusions","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":111},"commonTop":["Hypertension","Renal impairment"]}}}